Abstract:Objectives: Hypoxia is associated with human non-small cell lung cancers (NSCLC), which are highly resistant to chemotherapy. The hypoxia inducible factor (HIF) as a transcription factor in response to hypoxia indicates that it could be a novel, tumor-specific target for anticancer therapy. We hypothesized that disruption of HIF pathway through lentiviral vector-mediated HIF-1 alpha RNA interference (RNAi) could reverse the hypoxia-induced resistance to chemotherapy. Methods: We transfected Human NSCLC cell lines, SPCA1 and A549 with HIF-1 alpha specific RNAi lentiviral vectors as well as controls. HIF-1 alpha silenced cells [SPCA1/HIF-1 alpha(-) and A549/HIF-1 alpha(-)] were screened by blasticidin. They were incubated in 19 or 0.5% O-2 for 16 h followed by the assessment of chemosensitivity to cisplatin and doxorubicin with MTT and clonogenic assays. Quantitative RT-PCR and Western blot analysis were used to detect the expressions of HIF-1 alpha mRNA and protein, respectively. Moreover, flow cytometry was used to monitor the expression of P-glycoprotein. Results: Exposure of SPCA1 and A549 cells to 0.5% O-2 significantly increased resistance to cisplatin and doxorubicin, in contrast to cells incubated in normoxia. Transduction of SPCA1 with HIF-1 alpha RNAi vector resulted in sequence specific silencing with 87.2 and 84.6% decreases of HIF-1 alpha mRNA transcription and 97.3 and 94.8% of protein expressions in normoxia and hypoxia, respectively. Correspondingly, they are 89.2, 89.9% and 97.2, 88.4% decreases in A549 cells. Hypoxia-induced resistance to cisplatin and doxorubicin were reversed in SPCA1/HIF-1 alpha(-) and A549/HIF-1 alpha(-) cells. There was no significant P-glycoprotein increase induced by hypoxia in NSCLC cells. Conclusions: Our studies demonstrated that hypoxia-induced chemoresistance to cisplatin and doxorubicin in NSCLC cells is through the HIF pathway. MDR1 regulation may not be involved in hypoxia-induced chemoresistance. Combining delivery of HIF-1 alpha RNAi lentiviral vector with cisplatin-related chemotherapy regimens may enable us to develop more effective strategy for NSCLC therapy.

Hypoxia-Inducible Factor-1 Alpha Contributes to Hypoxia-Induced Chemoresistance in Gastric Cancer

Chemoresistance is Associated with Overexpression of HAX-1, Inhibition of Which Resensitizes Drug-Resistant Breast Cancer Cells to Chemotherapy.

Regulation Of Energy Metabolism By Hypoxia-Inducible Factor 1 Alpha In Gastric Cancer Cells

Hypoxia‐mediated Up‐regulation of MGr1‐Ag/37LRP in Gastric Cancers Occurs Via Hypoxia‐inducible‐factor 1‐dependent Mechanism and Contributes to Drug Resistance

Involvement of MGr1-Ag/37LRP in the Vincristine-Induced HIF-1 Expression in Gastric Cancer Cells

The mechanism of hypoxia-induced multidrug resistance in gastric cancer

Involvement of Hypoxia-Inducible Factor-1Α in the Mechanism of Multidrug Resistance Phenotype in Gastric Cancer

Hypoxia-Induced Resistance To Cisplatin And Doxorubicin In Non-Small Cell Lung Cancer Is Inhibited By Silencing Of Hif-1 Alpha Gene

Enolase 1 Stimulates Glycolysis to Promote Chemoresistance in Gastric Cancer.

Activated HIF1α of Tumor Cells Promotes Chemoresistance Development Via Recruiting GDF15-producing Tumor-Associated Macrophages in Gastric Cancer.

Hypoxia-Induced Autophagy Enhances Cisplatin Resistance in Human Bladder Cancer Cells by Targeting Hypoxia-Inducible Factor-1α

Up‐regulation of Survivin by AKT and Hypoxia‐inducible Factor 1α Contributes to Cisplatin Resistance in Gastric Cancer

HIF-1α Inhibition Reverses Multidrug Resistance in Colon Cancer Cells via Downregulation of MDR1/P-Glycoprotein

Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells

HIF1α/VEGF Feedback Loop Contributes to 5-Fluorouracil Resistance

Meta-analysis of Immunohistochemical Expression of Hypoxia Inducible Factor-1Α As a Prognostic Role in Gastric Cancer.

Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene

The hypoxia-inducible factor-1α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting

Cetuximab Enhances the Effect of Oxaliplatin on Hypoxic Gastric Cancer Cell Lines.

Basal and therapy-driven hypoxia-inducible factor-1 alpha confers resistance to endocrine therapy in estrogen receptor-positive breast cancer

Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1α/miR-338-5p/IL-6 Feedback Loop.